Clinical Trials | February 14, 2024
Roche launches three new Factor Xa inhibitor coagulation tests
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
The company has received five final approvals
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Subscribe To Our Newsletter & Stay Updated
